<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-provides-regulatory-update-deramiocel-bla-duchenne-muscular</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-21T00:55:00.000Z</news:publication_date>
      <news:title>Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRM/medirom-regains-compliance-nasdaq-filing-requirement</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T23:42:00.000Z</news:publication_date>
      <news:title>MEDIROM Regains Compliance with Nasdaq’s Periodic Filing Requirement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SGRY/surgery-partners-consent-solicitation-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:49:00.000Z</news:publication_date>
      <news:title>Surgery Partners, Inc. Announces Expiration and Results of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALPS/alps-group-regains-nasdaq-compliance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:15:00.000Z</news:publication_date>
      <news:title>Alps Group Inc Regains Compliance with Nasdaq Minimum Bid Price Requirement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:15:00.000Z</news:publication_date>
      <news:title>Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-settlement-notice-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:00:00.000Z</news:publication_date>
      <news:title>Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reverse-stock-split</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:35:00.000Z</news:publication_date>
      <news:title>Theriva™ Biologics Announces Reverse Stock Split</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABVX/abivax-statement-short-seller-report</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:33:00.000Z</news:publication_date>
      <news:title>Abivax Statement on Short Seller Report</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MTD/mettlertoledo-present-evercore-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>Mettler-Toledo International Inc. to Present at Upcoming Investor Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TEVA/teva-presents-at-upcoming-healthcare-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RLYB/avenzo-therapeutics-merger-rallybio</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BON/bon-joint-lab-natural-ingredients-biomanufacturing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>BON Unveils Joint Lab for Natural Ingredients &amp; Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inducement-grants-nasdaq-5635c4</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:05:00.000Z</news:publication_date>
      <news:title>Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:05:00.000Z</news:publication_date>
      <news:title>InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-evercore-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:04:00.000Z</news:publication_date>
      <news:title>AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CDNA/caredx-participate-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:01:00.000Z</news:publication_date>
      <news:title>CareDx to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-public-offering-172-million</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:01:00.000Z</news:publication_date>
      <news:title>SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-broadens-phase-2b-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:01:00.000Z</news:publication_date>
      <news:title>Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-new-employees-nasdaq-listing-rule</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:00:00.000Z</news:publication_date>
      <news:title>Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/XCUR/exicure-expands-parkinsons-disease-market</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T18:00:00.000Z</news:publication_date>
      <news:title>Exicure Announces Strategic Expansion into Parkinson’s Disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SRXH/srx-global-engineered-t-cell-strategy-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T17:58:00.000Z</news:publication_date>
      <news:title>SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-pynnacle-phase-2-trial-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T15:30:00.000Z</news:publication_date>
      <news:title>PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GSK/gsk-transfer-treasury-shares</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T15:25:38.000Z</news:publication_date>
      <news:title>Transfer of Treasury Shares</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MMM/3m-announces-upcoming-investor-event-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T15:15:00.000Z</news:publication_date>
      <news:title>3M Announces Upcoming Investor Event</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/cvs-home-team-heroes-soccer-contest-winners</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:40:00.000Z</news:publication_date>
      <news:title>CVS Pharmacy® names Grand Prize winners of first Home Team Heroes youth soccer contest</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMCC/im-cannabis-new-ceo-ronen-zalayet</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:19:00.000Z</news:publication_date>
      <news:title>IM Cannabis Corp. Appoints New CEO to Lead Technology-Driven Business Expansion</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PPBT/purple-biotech-im1240-eortc-nci-aacr-symposium</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Purple Biotech&apos;s IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JAGX/jaguar-health-reverse-stock-split-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Jaguar Health, Inc. Announces Reverse Stock Split</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GEHC/ge-healthcare-imaging-360-ai-features</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>GE HealthCare introduces new Imaging 360 features to simplify protocol management and support radiology workflows</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-1-results-apr-1051</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVNO/envveno-medical-three-year-data-veith-symposium</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:41:00.000Z</news:publication_date>
      <news:title>enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BTCY/biotricity-reports-q2-fiscal-2027-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:35:00.000Z</news:publication_date>
      <news:title>Biotricity Reports Second Quarter Fiscal 2027 Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SVRA/savara-fda-molgramostim-bla-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:30:00.000Z</news:publication_date>
      <news:title>Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-blood-test-cte-study</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:30:00.000Z</news:publication_date>
      <news:title>JAMA Study Using Alamar Biosciences’ NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players with Advanced CTE</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-ncl-conference-ntsad-event</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:30:00.000Z</news:publication_date>
      <news:title>Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine &amp; Believe Event</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NCNA/nucana-nuc-7738-carfilzomib-multiple-myeloma</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:47.000Z</news:publication_date>
      <news:title>NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-presentations-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Alnylam to Webcast Presentations at Upcoming December Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVM/celsci-multikine-nadr-designation-saudi-fda</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABBV/abbvie-piper-sandler-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-625-million-financing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLTE/belite-bio-fda-review-timeline-extension-tinlarebant</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMDX/imdex-graftassure-galactic-registry-study-launch</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANVS/annovis-fda-agreement-safety-plan-buntanetap-nda</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-ash-2026-events</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-phase-4-results-psoriatic-arthritis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Late-breaking Johnson &amp; Johnson data in psoriatic arthritis (PsA) shows TREMFYA® (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DHR/danaher-microsoft-smart-scientific-instruments</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:30:00.000Z</news:publication_date>
      <news:title>Danaher Collaborates with Microsoft to Make Scientific Instruments Agentically Connected and Laboratories More Intelligent</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRIO/dario-ceo-erez-raphael-panel-us-bancorp-forum</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:30:00.000Z</news:publication_date>
      <news:title>Dario CEO Erez Raphael to Lead Panel Discussion at U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HSCS/heartsciences-shareholders-approve-business-combination</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:30:00.000Z</news:publication_date>
      <news:title>HeartSciences Shareholders Approve Proposed Business Combination with Fortitude Mining</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HLF/herbalife-cfo-fireside-chat-bofa-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:05:00.000Z</news:publication_date>
      <news:title>Herbalife CFO to Participate in Fireside Chat at Bank of America Leveraged Finance Conference on December 1</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-grant-inducement-awards-nasdaq-listing-rule-5635</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:01:00.000Z</news:publication_date>
      <news:title>Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/UTHR/first-transplant-extend-clinical-trial-uthymokidney</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:00:00.000Z</news:publication_date>
      <news:title>United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:00:00.000Z</news:publication_date>
      <news:title>Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ERAS/erasca-phase-1-data-eras-0015</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:00:00.000Z</news:publication_date>
      <news:title>Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRK/merck-trofuse-015-trial-sacituzumab-tirumotecan-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T11:45:00.000Z</news:publication_date>
      <news:title>Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-q3-2026-financial-results-call</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:00:00.000Z</news:publication_date>
      <news:title>ADDEX THERAPEUTICS TO REPORT 2026 THIRD QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 25, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-3-billion-senior-notes</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T01:45:00.000Z</news:publication_date>
      <news:title>Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ILMN/illumina-wins-virtual-cell-challenge</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T01:00:00.000Z</news:publication_date>
      <news:title>Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MESO/mesoblast-deloitte-tech-fast-50-award</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T23:51:00.000Z</news:publication_date>
      <news:title>Mesoblast Wins Deloitte Tech Fast 50 Leadership &amp; Enterprise Growth Award</news:title>
    </news:news>
  </url>
</urlset>